Cargando…
Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?
Targeted therapies have become a mainstay in the treatment of cancer, but their long‐term efficacy is compromised by acquired drug resistance. Acquired therapy resistance develops via two phases—first through adaptive development of nongenetic drug tolerance, which is followed by stable resistance t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061276/ https://www.ncbi.nlm.nih.gov/pubmed/36852624 http://dx.doi.org/10.1002/1878-0261.13406 |